Skip to main content
SpringerLink
Log in

Combination treatment with Interleukin-2 and chemotherapeutic agents

  • Chapter
Book cover The role of interleukin-2 in the treatment of cancer patients

  • 125 Accesses

Abstract

Most malignant tumours are still incurable in advanced stages. Surgery and radiotherapy certainly have an established role, but systemic treatment, usually chemotherapy, is considered standard treatment for disseminated malignancies. The activity of cytotoxic drugs is often unsatisfactory, and additional therapeutic options are clearly needed. Immunotherapy has emerged as a fourth modality for the treatment of certain malignant tumours [1] since recombinant materials became available for clinical use. Interleukin-2 (IL-2) is a cytokine which, when used as a single agent, showed activity against a range of tumours in both preclinical and clinical studies. More recently, IL-2 has been combined with chemotherapeutic drugs, and the number of studies investigating this approach is rapidly increasing. This review will summarise the clinical studies on IL-2 based chemoimmunotherapy published so far, but some general aspects concerning the combined use of IL-2 and chemotherapy will be considered first.

A. von Rohr is supported by the European Society for Medical Oncology (ESMO)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Oldham R. Biotherapy: The fourth modality of cancer treatment. J Cell Physiol 1986; 4(Suppl): 91–9.

    Article  CAS  Google Scholar 

  2. Papa MZ, Yang JC, Vetto JT, et al. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 1988; 48: 122–9.

    PubMed  CAS  Google Scholar 

  3. LoRusso PM, Aukerman SL, Polin L, et al. Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems. Cancer Res 1990; 50: 5876–82.

    PubMed  CAS  Google Scholar 

  4. Silagi S, Schaefer AE. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide. J Biol Response Mod 1986; 5: 411–22.

    PubMed  CAS  Google Scholar 

  5. Wiltrout RH, Salup RR. Adoptive immunotherapy in combination with chemotherapy for cancer treatment. Prog Exp Tumor Res 1988; 32: 128–53.

    PubMed  CAS  Google Scholar 

  6. Kedar E, Ben-Aziz R, Shiloni E. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells. Isr J Med Sci 1988; 24: 494–504.

    PubMed  CAS  Google Scholar 

  7. Hosokawa M, Yabiku T, Ikeda J, et al. Effects of a combination of cyclophosphamide and human recombinant interleukin 2 on pulmonary metastasis after the surgical removal of a 3-methylcholanthrene-induced primary tumor in autochthonous mice. Jpn J Cancer Res(Gann)1988; 79: 1147–54.

    Article  CAS  Google Scholar 

  8. Hosokawa M, Sawamura Y, Morikage T, et al. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother 1988; 26: 250–6.

    Article  PubMed  CAS  Google Scholar 

  9. Eggermont AMM, Sugarbaker PH. Efficacy of chemoimmunotherapy with cyclophospha-mide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Cancer 1988; 58: 410–4.

    Article  PubMed  CAS  Google Scholar 

  10. Eggermont AMM, Sugarbaker PH. Augmentation of antitumor effects of intraperitoneal (ip) interleukin-2 (IL-2) by monoclonal antibodies (MoAbs) and cyclophosphamide (CY). Proc AACR 1989;30:376(# 1493).

    Google Scholar 

  11. Gambacorti-Passerini C, Radrizzani M, Erba E, et al. Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide. Cancer Res 1987; 47: 2547–52.

    PubMed  CAS  Google Scholar 

  12. Gambacorti-Passerini C, Rivoltini L, Supino R, et al. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res 1988; 48: 2372–6.

    PubMed  CAS  Google Scholar 

  13. Allavena P, Grandi M, D’lncalci M, et al. Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes. Int J Cancer 1987; 40: 104–7.

    Article  PubMed  CAS  Google Scholar 

  14. Allavena P, Damia G, Colombo T, et al. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cell Immunol 1989; 120: 250–8.

    Article  PubMed  CAS  Google Scholar 

  15. Schroit AJ, Fidler IJ. The use of activated macrophages for the destruction of heterogeneous metastasis. In: Horn KV, Powers WE, Sloane BF, editors. Mechanisms of cancer metastasis: Potential therapeutic implications. Boston: M. Nijhoff, 1986: 207–26.

    Google Scholar 

  16. Harker WG, Tom C, McGregor JR, et al. Human tumor cell line resistance to chemo-therapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Cancer Res 1990; 50: 5931–6.

    PubMed  CAS  Google Scholar 

  17. Mulé JJ, Yang JC, Lafreniere R, et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 1987; 139: 285–94.

    PubMed  Google Scholar 

  18. Mertelsmann R, Welte K. Restorative immunotherapy with interleukin-2. In: Reif AE, Mitchell MS, editors. Immunity to cancer. Orlando: Academic Press, 1985: 485–97.

    Google Scholar 

  19. Ades EW, McKemie CR III, Wright S, et al. Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: Protocol for enhanced tumoricidal activity. Nat Immun Cell Growth Regul 1987; 6: 260–8.

    PubMed  CAS  Google Scholar 

  20. Mitchell MS. Biomodulation: A classification and overview. In: Reif AE, Mitchell MS, editors. Immunity to cancer. Orlando: Academic Press, 1985: 401–11.

    Google Scholar 

  21. Chabot GG, Flaherty LE, Valdivieso M, Baker LH. Alteration of dacarbazine pharmakokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother Pharmacol 1990; 27: 157–60.

    Article  PubMed  CAS  Google Scholar 

  22. Schlager SI. Relationship between cell mediated and humoral immune attack on tumour cells.I. Drug and hormonal effects on susceptibility to killing and macromolecular synthesis. Cell Immunol 1981; 58: 398–414.

    Article  PubMed  CAS  Google Scholar 

  23. Schlager SI. Relationship between cell mediated and humoral immune attack on tumour cells.II. The role of cellular lipid metabolism and cell surface charge in the outcome of immune attack. Cell Immunol 1982; 66: 300–16.

    Article  PubMed  CAS  Google Scholar 

  24. Borsos T. Induction of tumour immunity by intratumoral chemotherapy. Ann N Y Acad Sci 1976; 276: 565–80.

    Article  PubMed  CAS  Google Scholar 

  25. Mathé G. Effectiveness of murine leukemia chemotherapy according to the immune status. Cancer Immunol Immunother 1977; 2: 139–41.

    Google Scholar 

  26. Braun DP, Harris JE. Modulation of the immune response by chemotherapy. Pharmacol Ther 1981; 14: 89–122.

    Article  PubMed  CAS  Google Scholar 

  27. Kempf RA, Mitchell MS. Effects of chemotherapeutic agents on the immune response. I. Cancer Invest 1984; 2: 459–66.

    Article  CAS  Google Scholar 

  28. Kempf RA, Mitchell MS. Effects of chemotherapeutic agents on the immune response. II. Cancer Invest 1985; 3: 23–33.

    Article  CAS  Google Scholar 

  29. Mulé JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 1985; 135: 646–52.

    PubMed  Google Scholar 

  30. Mastrangelo MJ, Berd D, Maguire H Jr. The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol 1986; 13: 186–94.

    PubMed  CAS  Google Scholar 

  31. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: Reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 1987; 47: 3317–21.

    PubMed  CAS  Google Scholar 

  32. Berd D, Maguire HC Jr, Mastrangelo MJ. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res 1984; 44: 1275–80.

    PubMed  CAS  Google Scholar 

  33. Glaser M. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice depleted of suppressor T cells with cyclophosphamide. Cell Immunol 1979; 48: 339–45.

    Article  PubMed  CAS  Google Scholar 

  34. Eiseman J, Melink T, Bell M, et al. Determination of an optimal immunomodulatory dose for cyclophosphamide in combination with interleukin-2. Proc AACR 1989; 30: 378 (# 1501).

    Google Scholar 

  35. Kedar E, Ben-Aziz R, Epstein E, Leshem B. Chemoimmunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type. Cancer Immunol Immunother 1989; 29: 74–8.

    Article  PubMed  CAS  Google Scholar 

  36. Kedar E, Chriqui-Zeira E, Kyriazis AP. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2 propagated lymphocytes. J Biol Response Mod 1984; 3: 517–26.

    PubMed  CAS  Google Scholar 

  37. Yu PP, Paciucci PA, Holland JF. Activity of human recombinant interleukin-2 (rIL-2) and doxorubicin in tumour-bearing BL/6 mice. Proc AACR 1986; 27: 317 (# 1258).

    Google Scholar 

  38. Salup RR, Back TC, Wiltrout RH. Successful treatment of advanced murine renal cell cancer by bicompartemental adoptive chemoimmunotherapy. J Immunol 1987; 138: 641–7.

    PubMed  CAS  Google Scholar 

  39. Ehrke MJ, Ryoyama K, Cohen SA. Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res 1984; 44: 2497–2504.

    PubMed  CAS  Google Scholar 

  40. Ehrke MJ, Ryoyama K, Mihich E. Generation of cytotoxic lymphocytes in cultures of spleen cells from tumor bearing mice: Modification by adriamycin and cyclophosphamide treatment of the mice. Proc AACR 1981; 22: 273.

    Google Scholar 

  41. Ehrke MJ, Maccubbin D, Ryoyama K, et al. Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res 1986; 46: 54–60.

    PubMed  CAS  Google Scholar 

  42. Kempf RA, Cebul RA, Mitchell MS. Antitumour effects of doxorubicin against a virally-induced rat osteosarcoma with minimal immunosuppression. J Immunopharmacol 1980; 2: 509–25.

    Article  PubMed  CAS  Google Scholar 

  43. Mantovani A, Luini W, Peri G, et al. Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst 1978; 61: 1255–61.

    PubMed  CAS  Google Scholar 

  44. Spreafico F. Heterogeneity of the interaction of anticancer agents with the immune system and its possible relevance to chemoimmunotherapy. Oncology 1980; 37(Suppl 1): 9–18.

    Article  PubMed  CAS  Google Scholar 

  45. Paciucci PA, Holland JF, Ryder JS, et al. Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin. Cancer Treat Rev 1989; 16(Suppl A): 67–81.

    Article  PubMed  Google Scholar 

  46. Kleinerman ES, Zwelling LA, Muchmore AV. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum(II). Cancer Res 1980; 40: 3099–3102.

    PubMed  CAS  Google Scholar 

  47. Sodhi A, Bhatia P. In vitro activation of murine macrophages and their increased capacity to lyse target cells after cisplatin treatment. Indian J Exp Biol 1986; 24: 565–72.

    PubMed  CAS  Google Scholar 

  48. Gupta P, Sodhi A. Increased release of interleukin-1 from mouse peritoneal macrophages in vitro after cisplatin treatment. Int J Immunopharmacol 1987; 9: 385–8.

    Article  PubMed  CAS  Google Scholar 

  49. Lichtenstein AK, Pende D. Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro. Cancer Res 1986; 46: 639–44.

    PubMed  CAS  Google Scholar 

  50. Allavena P, Pirovano P, Bonazzi C, et al. In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells. J Natl Cancer Inst 1990; 82: 139–42.

    Article  PubMed  CAS  Google Scholar 

  51. Redman BG, Flaherty L, Chou TH, et al. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: Immunological effects of therapy. J Immunother 1991; 10: 147–51.

    Article  PubMed  CAS  Google Scholar 

  52. Contessa AR, Bonmassar A, Giampietri A, et al. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3-Dimethyl-l-triazeno)imidazole-4-carboxamide. Cancer Res 1981; 41: 2476–82.

    PubMed  CAS  Google Scholar 

  53. Nicolin A, Bini A, Coronetti E, Goldin A. Cellular immune response to a drug-treated L5178Y lymphoma subline. Nature 1974; 251: 654–5.

    Article  PubMed  CAS  Google Scholar 

  54. Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A. Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Natl Acad Sci USA 1970; 66: 1089–95.

    Article  PubMed  CAS  Google Scholar 

  55. Fioretti MC, Bianchi R, Romani L, Bonmassar E. Drug-induced immunogenic changes of murine leukemia cells: Dissociation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst 1983; 71: 1247–51.

    PubMed  CAS  Google Scholar 

  56. Franco P, Veronese F, Levi F, et al. Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma. Br J Cancer 1982; 46: 173–9.

    Article  PubMed  CAS  Google Scholar 

  57. Kohler PC, Hank JA, Moore KH, et al. Phase I clinical trial of recombinant interleukin-2: A comparison of bolus and continuous intravenous infusion. Cancer Invest 1989; 7: 213–23.

    Article  PubMed  CAS  Google Scholar 

  58. Thompson JA, Lee DJ, Lindgren CG, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6: 669–78.

    PubMed  CAS  Google Scholar 

  59. Mitchell MS, Kempf RA, Harel W, et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988; 6: 409–24.

    PubMed  CAS  Google Scholar 

  60. Mitchell MS, Kempf RA, Harel W, et al. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma. Bull N Y Acad Med 1989; 65: 128–44.

    PubMed  CAS  Google Scholar 

  61. Lindemann A, Hoeffken K, Schmidt RE, et al. A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies. Cancer Treat Rev 1989; 16(Suppl A):53–7.

    Article  PubMed  Google Scholar 

  62. Croghan M, Hersh EM, Taylor C, et al. Phase I-II study of low dose cytoxan and recombinant interleukin-2 (IL-2) for the treatment of disseminated carcinoma. Proc ASCO 1989; 8: 180 (# 699).

    Google Scholar 

  63. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–85.

    Article  PubMed  CAS  Google Scholar 

  64. Shiloni E, Pouillart P, Janssens J, et al. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study. Eur J Cancer Clin Oncol 1989; 25(Suppl 3): S45–S49.

    PubMed  Google Scholar 

  65. Dummer R, Becker J, Schulz A, et al. DTIC and sequential IL-2 for metastatic malignant melanoma. Eur J Cancer 1991; 27(Suppl 2): S153 (# 919).

    Google Scholar 

  66. Dorreen MS, Sreenivasan T, Bruce L, et al. Biological responses in patients undergoing interleukin-2 therapy for metastatic melanoma and renal cell carcinoma. Proc ASCO 1990; 9: 192 (# 744).

    Google Scholar 

  67. Flaherty L, Redman B, Chabot G, et al. Combination of dacarbazine (DTIC) and interleukin-2 (IL-2) in metastatic malignant melanoma (MMM). Proc ASCO 1988; 7: 254 (# 983).

    Google Scholar 

  68. Flaherty L. The combination of recombinant interleukin-2 and dacarbazine (DTIC) in metastatic malignant melanoma. Cancer Treat Rev 1989; 16(Suppl A): 65–6.

    Article  Google Scholar 

  69. Flaherty LE, Redman BG, Chabot GG, et al. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 1990; 65: 2471–7.

    Article  PubMed  CAS  Google Scholar 

  70. Papadopoulos NEJ, Howard J, Murray JL, et al. Phase I-II DTIC and interleukin-2 (IL-2) trial for metastatic malignant melanoma. Proc ASCO 1989; 8: 290 (# 1130).

    Google Scholar 

  71. Papadopoulos NEJ, Howard JG, Murray JL, et al. Phase II DTIC and interleukin 2 (IL-2) trial for metastatic malignant melanoma. Proc ASCO 1990; 9: 277 (# 1072).

    Google Scholar 

  72. Stoter G, Shiloni E, Gundersen S, et al. Alternating recombinant human interleukin-2 (rIL-2) and dacarbazine (DTIC) in metastatic melanoma. Proc ASCO 1989; 8: 281 (# 1095).

    Google Scholar 

  73. Stoter G, Shiloni E, Gundersen S, et al. Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study. Cancer Treat Rev 1989; 16(SupplA): 59–63.

    Article  PubMed  Google Scholar 

  74. Stoter G, Shiloni E, Aamdal S, et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study. Eur J Cancer Clin Oncol 1989; 25(Suppl 3): S41–S43.

    PubMed  Google Scholar 

  75. Stoter G, Aamdal S, Rodenhuis S, et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: A multicenter phase II study. J Clin Oncol 1991; 9: 1687–91.

    PubMed  CAS  Google Scholar 

  76. West W, Tauer K, Barth N, et al. Adoptive immunotherapy and sequential DTIC chemo-therapy in metastatic melanoma. Proc ASCO 1989; 8: 281 (# 1094).

    Google Scholar 

  77. Dillman RO, Oldham RK, Barth NM, et al. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in malignant melanoma: A National Biotherapy Study Group trial. J Natl Cancer Inst 1990; 82: 1345–9.

    Article  PubMed  CAS  Google Scholar 

  78. Blair S, Flaherty L, Valdivieso M, Redman B. Comparison of high dose interleukin-2 (HD IL-2) with combined chemotherapy/low dose IL-2 (chemo/IL-2) in metastatic malignant melanoma. Proc ASCO 1991; 10: 294 (# 1031).

    Google Scholar 

  79. Atkins M, Demchak P, Mier J, et al. Phase II study of alternating interleukin-2 (IL-2) and cisplatin (cisDDP) with WR-2721 in metastatic melanoma. Proc ASCO 1989; 8: 287 (# 1119).

    Google Scholar 

  80. Demchak PA, Mier JW, Robert NJ, et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study. J Clin Oncol 1991; 9: 1821–30.

    PubMed  CAS  Google Scholar 

  81. Wiltrout RH, Boyd MR, Back TC, et al. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol 1988; 140: 3261–5.

    PubMed  CAS  Google Scholar 

  82. Hornung RL, Young HA, Urba WJ, Wiltrout RH. Immunomodulation of natural killer cell activity by flavone acetic acid: Occurrence via induction of interferon α / ß. J Natl Cancer Inst 1988; 80: 1226–31.

    Article  PubMed  CAS  Google Scholar 

  83. Urba WJ, Longo DL, Lombardo FA, Weiss RB. Enhancement of natural killer activity in human peripheral blood by flavone acetic acid. J Natl Cancer Inst 1988; 80: 521–5.

    Article  PubMed  CAS  Google Scholar 

  84. Thatcher N, Dazzi H, Mellor M, et al. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: A phase II study. Br J Cancer 1990; 61:618–21.

    Article  PubMed  CAS  Google Scholar 

  85. Sznol M, Clark J, Smith J, et al. A pilot evaluation of interleukin-2 (IL-2) and lymphokine activated killer (LAK) cells in combination with chemotherapy and alpha-interferon. Proc ASCO 1989; 8: 191 (# 742).

    Google Scholar 

  86. Sznol M, Clark J, Smith J, et al. A phase II study of IL-2/LAK in combination with chemotherapy and interferon-alfa in patients with metastatic melanoma and renal cell carcinoma (RCC). Proc ASCO 1990; 9: 196 (# 759).

    Google Scholar 

  87. Hamblin TJ, Davies B, Sadullah S, et al. A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cis-platin, interleukin-2 (IL-2) and alfa-interferon (IFN). Proc ASCO 1991; 10: 294 (# 1029).

    Google Scholar 

  88. Hamblin TJ, Davies B, Sadullah S, et al. A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cis-platin, interleukin-2 (IL-2) and alfa-interferon (IFN). Eur J Cancer 1991; 27(Suppl 2): S157 (# 939).

    Google Scholar 

  89. Kirchner H, Poliwoda H, Atzpodien J. Recombinant interleukin-2 and interferon-α in combination with carboplatin and DTIC in progressive metastatic melanoma. Eur J Cancer 1991; 27(Suppl 2): S157 (# 942).

    Google Scholar 

  90. Richards JM, Priest E, Hamasaki V, et al. Sequential chemoimmunotherapy for metastatic melanoma. Proc ASCO 1991; 10: 298 (# 1046).

    Google Scholar 

  91. Kolitz JE, Merluzzi VJ, Welte K, et al. A phase I trial of recombinant interleukin-2 (rIL-2) and cyclophosphamide (CPM) in advanced malignancy. Proc ASCO 1986; 5: 235 (# 921).

    Google Scholar 

  92. Kolitz JE, Wong GY, Welte K, et al. Phase I trial of recombinant interleukin-2 and cyclophosphamide: Augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. J Biol Response Mod 1988; 7: 457–72.

    PubMed  CAS  Google Scholar 

  93. Pinto HA, Yahanda A, Reese J, et al. Chemoimmunotherapy with recombinant interleukin-2 (rIL-2) and vinblastine (VBL) in metastatic renal cell carcinoma. Proc ASCO 1991; 10: 179 (# 579).

    Google Scholar 

  94. Bar MH, Valone FH, Rayner AA, et al. A phase I-II trial of combined interleukin-2 and vinblastine for metastatic renal cell carcinoma. Proc ASCO 1990; 9: 146 (# 568).

    Google Scholar 

  95. Hiddemann W, Ruelfs C, Ottensmeier C, et al. Combination of interleukin 2 with 5-fluorouracil and folinic acid in refractory colorectal cancer. Eur J Cancer 1991; 27(Suppl 2):S93(# 540).

    Google Scholar 

  96. Hamblin TJ, Inzani V, Sadullah S, et al. A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma. Cancer Treat Rev 1989; 16(Suppl A): 163–7.

    Article  PubMed  Google Scholar 

  97. Valone FH, Gandara DR, Deisseroth A, et al. Interleukin-2 (IL-2) combined with high-dose cisplatin (HDCP)/5-fluorouracil (5-FU) in metastatic non-small cell lung (NSCLC) and head and neck cancer. Proc ASCO 1989; 8: 194 (# 755).

    Google Scholar 

  98. Dimery I, Martin T, Bradley E, et al. Phase I trial of interleukin-2 (rIL-2) plus cisplatin (CDDP) and 5-fluorouracil (5-FU) in recurrent or advanced squamous cell carcinoma of the head and neck. Proc ASCO 1989; 8: 170 (# 660).

    Google Scholar 

  99. Merrouche Y, Negrier S, Rebattu P, et al. A phase II study of interleukin 2 (IL2) following high dose BCNU and autologous bone marrow transplantation (ABMT) in the treatment of metastatic gastric cancer. Proc ASCO 1991; 10: 161 (# 510).

    Google Scholar 

  100. Akiyoshi T, Arinaga S, Karimine N, et al. Effect of recombinant interleukin 2 in combination with mitomycin C or adriamycin on advanced cancer. Proc AACR 1990; 31: 273 (# 1616).

    Google Scholar 

  101. Clamon G, Goutsou M, Perry MC, et al. Interleukin-2 (IL-2) in extensive small cell lung cancer: A preliminary suggestion of activity. Proc ASCO 1991; 10: 267 (# 925).

    Google Scholar 

  102. Favrot MC, Michon J, Floret D, et al. Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation. Pediatr Hematol Oncol 1990; 7: 275–84.

    Article  PubMed  CAS  Google Scholar 

  103. Favrot MC, Floret D, Negrier S, et al. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 1989; 4: 499–503.

    PubMed  CAS  Google Scholar 

  104. Kawata A, Uchino J, Une Y, et al. Early postoperative chemoimmunotherapy with adriamycin, rIL-2 and spleen-derived LAK for hepatocellular carcinoma patients. Proc AACR 1991; 32: 251 (# 1490).

    Google Scholar 

  105. Dave HPG, Goldberg SL, Conde M, et al. Outpatient low-dose interleukin-2 with or without 5-fluorouracil/leucovorin for solid tumors. Proc ASCO 1991; 10: 217 (# 729).

    Google Scholar 

  106. Oldham RK, Stark J, Barth N, et al. Treatment of advanced cancers with cytoxan (CTX) and interleukin-2 (rIL-2): a phase II study. Proc AACR 1990; 31: 268 (# 1587).

    Google Scholar 

  107. Eggermont AMM, Marquet RL, De Bruin RWF, Jeekel J. Effects of the interferon inducer ABPP on colon cancer in rats; importance of tumor load and tumor site. Cancer Immunol Immunother 1986; 22: 217–22.

    Article  PubMed  CAS  Google Scholar 

  108. Greenberg PD, Klarnet JP, Kern DE, Cheever MA. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog Exp Tumor Res 1988; 32: 104–27.

    PubMed  CAS  Google Scholar 

  109. Gottlieb DJ, Brenner MK, He H, et al. A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: Applicability to the elimination of minimal residual disease. Br J Cancer 1989; 60: 610–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Albert Von Rohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nick Thatcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oncology, Free University Hospital, De Boelelaan 1117, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

    John Wagstaff MD, MB, ChB, MRCP (Senior Lecturer in Medical Oncology) (Senior Lecturer in Medical Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Von Rohr, A., Thatcher, N. (1993). Combination treatment with Interleukin-2 and chemotherapeutic agents. In: Wagstaff, J. (eds) The role of interleukin-2 in the treatment of cancer patients. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1753-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-1753-1_7

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4769-2

  • Online ISBN: 978-94-011-1753-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation